title: Development of human-human hybridoma from anti-Her-2 peptide-producing B cells in immunized NOG mouse.
abstract: OBJECTIVE
  Numerous monoclonal antibodies have been developed for the purpose of medical treatments, including cancer treatment. For clinical application, the most useful are human-derived antibodies. In this study, we tried to prepare designed antigen-specific antibodies of completely human origin using immunodeficient mouse.
  
  
  METHODS
  Nonobese diabetic/severe combined immunodeficient/IL-2 receptor gamma null mouse (NOG) mouse was used to reconstitute the human immune system with umbilical cord blood hematopoietic stem cells (CB-NOG mouse) and to prepare human-derived Her-2-epitope-specific antibodies. Hybridoma lines were prepared by fusing the human myeloma cell line Karpas707H.
  
  
  RESULTS
  Serum of immunized NOG mouse contained human-derived immunoglobulin M (IgM) antibodies specific for a short peptide sequence of 20 amino acids, including the epitope peptide of apoptotic Her-2 antibody CH401. Hybridoma lines were successfully prepared with spleen B cells obtained from the immunized CB-NOG mouse. One of these cell lines produced human IgM against the epitope peptide that can recognize surface Her-2 molecule.
  
  
  CONCLUSIONS
  We could produce human-derived IgM antibody against Her-2 epitope peptide in CB-NOG mouse, succeeding in generation of human hybridoma-secreting IgM against a given peptide.
authors.affiliation: Department of Immunology, Tokai University School of Medicine, Kanagawa, Japan.
authors.forename: Yoshie
authors.initials: Y
authors.lastname: Kametani
authors.forename: Masashi
authors.initials: M
authors.lastname: Shiina
authors.forename: Ikumi
authors.initials: I
authors.lastname: Katano
authors.forename: Ryoji
authors.initials: R
authors.lastname: Ito
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ando
authors.forename: Kanae
authors.initials: K
authors.lastname: Toyama
authors.forename: Hideo
authors.initials: H
authors.lastname: Tsukamoto
authors.forename: Takuya
authors.initials: T
authors.lastname: Matsumura
authors.forename: Yuki
authors.initials: Y
authors.lastname: Saito
authors.forename: Dai
authors.initials: D
authors.lastname: Ishikawa
authors.forename: Takao
authors.initials: T
authors.lastname: Taki
authors.forename: Mamoru
authors.initials: M
authors.lastname: Ito
authors.forename: Kohzoh
authors.initials: K
authors.lastname: Imai
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tokuda
authors.forename: Shunichi
authors.initials: S
authors.lastname: Kato
authors.forename: Norikazu
authors.initials: N
authors.lastname: Tamaoki
authors.forename: Sonoko
authors.initials: S
authors.lastname: Habu
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology*; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods; D018985:Epitopes, B-Lymphocyte / Q000276:immunology* / Q000494:pharmacology; D006801:Humans; D006825:Hybridomas / Q000166:cytology / Q000276:immunology*; D007114:Immunization; D007075:Immunoglobulin M / Q000276:immunology* / Q000627:therapeutic use; D051379:Mice; D008817:Mice, Mutant Strains; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000276:immunology; D010455:Peptides / Q000276:immunology* / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D018183:Transplantation Chimera / Q000235:genetics / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D018985:Epitopes, B-Lymphocyte; D007075:Immunoglobulin M; D010455:Peptides; D018719:Erb-b2 Receptor Tyrosine Kinases